home / stock / sphdf / sphdf quote
Last: | $11.70 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $11.70 |
High: | $0 |
Low: | $0 |
Volume: | 59 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$11.7 | $0 | $11.7 | $0 | $0 | 59 | 02-26-2024 |
$11.7 | $11.7 | $11.7 | $11.7 | $11.7 | 300 | 02-22-2024 |
$11.25 | $0 | $11.25 | $0 | $0 | 6 | 02-13-2024 |
$11.25 | $11.25 | $11.25 | $11.25 | $11.25 | 522 | 01-26-2024 |
$11.7 | $0 | $11.7 | $0 | $0 | 150 | 12-28-2023 |
$11.7 | $0 | $11.7 | $0 | $0 | 12,590 | 12-27-2023 |
$11.7 | $0 | $11.7 | $0 | $0 | 1,000 | 12-21-2023 |
$11.7 | $0 | $11.7 | $0 | $0 | 719 | 12-14-2023 |
$11.7 | $0 | $11.7 | $0 | $0 | 830 | 12-12-2023 |
$11.7 | $11.7 | $11.7 | $11.7 | $11.7 | 510 | 12-11-2023 |
$13.35 | $0 | $13.35 | $0 | $0 | 2,500 | 10-25-2023 |
$13.35 | $0 | $13.35 | $0 | $0 | 1,700 | 10-23-2023 |
$13.35 | $13.35 | $13.35 | $13.35 | $13.35 | 457 | 10-20-2023 |
$9.4 | $0 | $9.4 | $0 | $0 | 2,500 | 10-19-2023 |
$9.4 | $0 | $9.4 | $0 | $0 | 503 | 10-18-2023 |
$9.4 | $9.4 | $9.4 | $9.4 | $9.4 | 960 | 10-13-2023 |
$0.68 | $0 | $0.68 | $0 | $0 | 2,745 | 04-04-2023 |
$0.68 | $0.68 | $0.68 | $0.68 | $0.68 | 300 | 04-03-2023 |
$1.2 | $1.2 | $1.2 | $1.2 | $1.2 | 120 | 01-03-2023 |
$1.41 | $1.41 | $1.41 | $1.41 | $1.41 | 500 | 12-27-2021 |
News, Short Squeeze, Breakout and More Instantly...
Santhera Pharms Hldgs Ltd Company Name:
SPHDF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full R...
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted...
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in Germany in January 2024 by Santhera AGAMREE is the first DMD...